Ireland· IE-PA-EU/1/25/1917/002
LYNOZYFIC 200 mg concentrate for solution for infusion
A medicinal product containing linvoseltamab, registered in Ireland by Regeneron Ireland Designated Activity Company.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
The record
At a glance
HPRA (Ireland)- Active substance
- Linvoseltamab
- Manufacturer
- Regeneron Ireland Designated Activity Company
- Country
- Ireland (IE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/25/1917/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Linvoseltamab in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumLynozyfic 200 mgRegeneron Ireland Designated Activity Company (DAC)
- CzechiaLYNOZYFICRegeneron Ireland Designated Activity Company, Dublin
- FinlandLYNOZYFICRegeneron Ireland Designated Activity Company (DAC)
- IcelandLynozyficRegeneron Ireland Designated Activity Company
- SwedenLYNOZYFIC 200 mg Koncentrat till infusionsvätska, lösningRegeneron Ireland Designated Activity Company
- United StatesLYNOZYFICRegeneron Pharmaceuticals, Inc.
- SpainLYNOZYFIC 200 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRegeneron Ireland Designated Activity Company
- NetherlandsLYNOZYFIC 200 mg concentraat voor oplossing voor infusieRegeneron Ireland Designated Activity Company
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lynozyfic
- Liechtenstein · Lynozyfic
- Norway · Lynozyfic
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bc230aa9-86f4-422d-a6bd-4c4e7367fd90 GET /v1/drugs/bc230aa9-86f4-422d-a6bd-4c4e7367fd90?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": null,
"strength": null,
"pa_number": "EU/1/25/1917/002",
"substances": [
"Linvoseltamab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about linvoseltamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.